Viking Therapeutics director exercises 60K options, sells 60K shares

Viking Therapeutics (VKTX) reported insider activity by a director on 10/27/2025.

Rhea-AI Filing Summary

Viking Therapeutics (VKTX) reported insider activity by a director on 10/27/2025. The director exercised stock options for 60,000 shares in total—16,000 at an exercise price of $4.48, 22,000 at $5.80, and 22,000 at $4.88.

On the same date, the director sold 60,000 shares at a $35.5713 weighted-average price, with sales occurring between $35.02 and $35.94. Following these transactions, the director beneficially owned 30,000 shares directly.

Option origins and terms disclosed include grants dated 01/02/2019 (expiring 01/02/2028), 01/04/2022 (expiring 01/04/2031), and 01/03/2023 (expiring 01/03/2032), each corresponding to the exercised amounts listed above.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Rowland Charles A Jr

Role Director

Sold 60,000 shs ($2.13M)

Approx. gross sale proceeds $2.13M

Approx. exercise cost $307K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	16,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	22,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	22,000	$0.00	$0.00
Grant/Award	Common Stock, par value $0.00001 per share	16,000	$4.48	$72K
Grant/Award	Common Stock, par value $0.00001 per share	22,000	$5.80	$128K
Grant/Award	Common Stock, par value $0.00001 per share	22,000	$4.88	$107K
Sale	Common Stock, par value $0.00001 per share	60,000	$35.5713	$2.13M

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock, par value $0.00001 per share — 30,000 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VKTX disclose on Form 4?

A director exercised options for 60,000 shares and sold 60,000 shares on 10/27/2025.

How many VKTX shares were sold and at what price?

The director sold 60,000 shares at a $35.5713 weighted-average price, within a $35.02–$35.94 range.

What VKTX options were exercised and at what strike prices?

Options exercised: 16,000 at $4.48, 22,000 at $5.80, and 22,000 at $4.88.

What are the remaining VKTX holdings after the transactions?

The reporting person beneficially owned 30,000 shares directly after the transactions.

What were the grant and expiration dates for the exercised VKTX options?

Grants dated 01/02/2019 (expires 01/02/2028), 01/04/2022 (expires 01/04/2031), and 01/03/2023 (expires 01/03/2032).

Was the sale price presented as a single or weighted-average figure?

It was a weighted-average price of $35.5713, with individual trades between $35.02 and $35.94.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/28/2025 - 07:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rowland Charles A Jr

(Last) (First) (Middle)

C/O VIKING THERAPEUTICS, INC.

9920 PACIFIC HEIGHTS BLVD, SUITE 350

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.00001 per share	10/27/2025		A		16,000	A	$4.48	46,000	D
Common Stock, par value $0.00001 per share	10/27/2025		A		22,000	A	$5.8	68,000	D
Common Stock, par value $0.00001 per share	10/27/2025		A		22,000	A	$4.88	90,000	D
Common Stock, par value $0.00001 per share	10/27/2025		S		60,000	D	$35.5713(1)	30,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.48	10/27/2025		M			16,000	01/02/2019	01/02/2028	Common Stock	16,000	$0	0	D
Stock Option (Right to Buy)	$5.8	10/27/2025		M			22,000	01/04/2022	01/04/2031	Common Stock	22,000	$0	0	D
Stock Option (Right to Buy)	$4.88	10/27/2025		M			22,000	01/03/2023	01/03/2032	Common Stock	22,000	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.02 to $35.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Michael Morneau, as Attorney-in-Fact	10/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.